{"id":"adenuric","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Cerebrovascular accident","Liver function tests abnormal","Myocardial infarction","Thromboembolic disorder"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":{"chemblId":"CHEMBL1164729","moleculeType":"Small molecule","molecularWeight":"316.38"},"aliases":["the reference product"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Flavin reductase (NADPH), ATP-binding cassette sub-family G member 2, Potassium voltage-gated channel subfamily H member 2"},"_scrapedAt":"2026-03-28T00:59:43.924Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Gout Prevention","diseaseId":"gout-prevention","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Hyperuricemia","diseaseId":"hyperuricemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05109936","phase":"PHASE3","title":"Immediate Prescription of a Hypouricemic Treatment, Febuxostat, Compared to Its Delayed Administration","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2023-08-02","conditions":"Gout","enrollment":128},{"nctId":"NCT03605212","phase":"PHASE1, PHASE2","title":"Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults","status":"TERMINATED","sponsor":"Menarini Group","startDate":"2017-02-27","conditions":"Tumor Lysis Syndrome","enrollment":30},{"nctId":"NCT04155918","phase":"PHASE2","title":"Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients","status":"COMPLETED","sponsor":"Arthrosi Therapeutics","startDate":"2020-02-03","conditions":"Gout Patients","enrollment":30},{"nctId":"NCT04352153","phase":"NA","title":"Role of Uralyt-U in Patients With Hyperuricemia","status":"UNKNOWN","sponsor":"Ai Peng","startDate":"2020-04-01","conditions":"Uric Acid Stones, Hyperuricemia","enrollment":102},{"nctId":"NCT03395977","phase":"NA","title":"Uric Acid Effects on Endothelium and Oxydative Stress","status":"COMPLETED","sponsor":"Erasme University Hospital","startDate":"2018-01-03","conditions":"Oxidative Stress, Endothelial Function, Cardiovascular System","enrollment":53},{"nctId":"NCT02338323","phase":"NA","title":"Compare the Renal Protective Effects of Febuxostat and Benzbromarone","status":"COMPLETED","sponsor":"Shanghai 10th People's Hospital","startDate":"2015-01","conditions":"Chronic Kidney Disease, Hyperuricemia, Abnormal Renal Function","enrollment":160},{"nctId":"NCT03918551","phase":"PHASE1","title":"Bioequivalence Study of Two Formulations of Febuxostat 120 mg Film-coated Tablets in Healthy Adult Volunteers After a Single Oral Dose Administration Under Fasting Conditions","status":"COMPLETED","sponsor":"Pharmtechnology LLC","startDate":"2019-05-03","conditions":"Bioequivalence","enrollment":50},{"nctId":"NCT02500641","phase":"PHASE4","title":"Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout","status":"COMPLETED","sponsor":"Menarini International Operations Luxembourg SA","startDate":"2015-08-17","conditions":"Gout","enrollment":196},{"nctId":"NCT02944214","phase":"NA","title":"Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients","status":"UNKNOWN","sponsor":"Shanghai 10th People's Hospital","startDate":"2016-10","conditions":"Chronic Kidney Disease, Hyperuricemia, Abnormal Renal Function","enrollment":800},{"nctId":"NCT01724528","phase":"PHASE3","title":"Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies","status":"COMPLETED","sponsor":"Menarini Group","startDate":"2012-10","conditions":"Tumor Lysis Syndrome","enrollment":346},{"nctId":"NCT01736514","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout","status":"COMPLETED","sponsor":"Astellas Pharma Taiwan, Inc.","startDate":"2011-03","conditions":"Gout","enrollment":109}],"_emaApprovals":[],"_faersSignals":[{"count":281,"reaction":"ACUTE KIDNEY INJURY"},{"count":125,"reaction":"ANAEMIA"},{"count":119,"reaction":"DIARRHOEA"},{"count":119,"reaction":"DRUG INTERACTION"},{"count":113,"reaction":"HYPERKALAEMIA"},{"count":111,"reaction":"RENAL FAILURE"},{"count":101,"reaction":"DIZZINESS"},{"count":101,"reaction":"PYREXIA"},{"count":89,"reaction":"FALL"},{"count":87,"reaction":"HYPOTENSION"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":10,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_3","status":"active","brandName":"Adenuric","genericName":"Adenuric","companyName":"Pharmtechnology LLC","companyId":"pharmtechnology-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adenuric, also known as Febuxostat, is a medication used to treat gout due to high uric acid levels. It is typically taken orally and is recommended for people who cannot take allopurinol.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}